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Abstract
Syncope and orthostatic intolerance (OI) are common clinical syndromes often requiring  
medical attention. The former is defined as transient loss of consciousness and postural tone due  
to self-limited cerebral hypo-perfusion, while the latter consists of inappropriate cardiovascular 
responses to upright posture such as occur with orthostatic hypotension (OH) or postural ortho-
static tachycardia syndrome. The most frequent causes of syncope and OI are conditions that 
temporarily disrupt essential moment-to-moment interaction between the autonomic nervous 
system and cardiovascular system. In this regard, many neuropeptides (NPs) or peptide hormon -
es (PH) exert cardio-active effects that might contribute to the pathophysiology of certain forms 
of syncope or OI. To date, the principal peptides that have been studied in this context are: atrial 
and B-type-neuropeptides, adrenomedullin, endothelin-1 (ET-1), galanin, and vasopressin. 
While definitive conclusions cannot yet be drawn, the intrinsic vasoconstrictor ET-1 appears 
to be elevated in OH, presumably to compensate for vasodilation and hypotension of other 
etiologies. As such elevated ET-1 may become a marker for OH. Further, elevated NT-proBNP 
may play a role in causing vasodilation and hypotension in some forms of OH of previously 
unknown cause, and may be a marker in other patients of a cardiovascular cause of syncope 
and OI. In the end, the study of the role of NPs and PHs in syncope and OI syndromes is at an 
early stage, and considerable further future effort is needed. (Cardiol J 2014; 21, 6: 591–600)
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Introduction
Syncope and orthostatic intolerance (OI) are 
common clinical conditions with many possible 
etiologies (Fig. 1) [1, 2]. By far the most frequent 
causes are conditions that transiently disrupt es-
sential moment-to-moment interaction between 
the autonomic nervous system (ANS) and the 
cardiovascular system (CVS); others include:
 — Adverse effects of a wide variety of drugs that 
operate through modification of CVS or nervous 
system responsiveness, or volume status;
 — Inadequate circulating volume such as may occur 
in older individuals exposed to hot dry environ-
ments or who have inadequate thirst drive;
 — Complications of cardiovascular disease, 
particularly cardiac arrhythmias;
 — Chronic diseases of the nervous system that 
result in hypotension during orthostatic stress 
or physical exertion.
In health, ANS and CVS work together to 
assure appropriate cerebral perfusion [3]. If this 
collaboration is disturbed, even briefly, cerebrovas­
cular blood flow may be compromised sufficiently 
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to cause complete or near loss of consciousness 
(i.e., syncope, near-syncope), or other frequent 
but less well­defined symptoms such as ‘dizzi-
ness’ and ‘lightheadedness’. For example, even 
temporary inappropriate partitioning of circulatory 
volumes among various vascular beds may result 
in excessive pooling of blood in the sub-diaphrag-
matic circulation; the result may be cerebral hypo-
-perfusion during upright posture (i.e., orthostatic 
intolerance) and it may be accompanied by syncope 
or near syncope.
Since most clinical disturbances of ANS-CVS 
control occur in the absence of evident structural 
ANS or CVS disease and have resolved before 
medical attention is sought (e.g., reflex faints such 
as vasovagal syncope), establishing the specific 
responsible etiology and pathophysiology of the 
patient’s symptoms is often challenging. On the 
other hand, understanding of the specific cause and 
the pathophysiology provides the necessary foun-
dation needed to devise effective therapy for pre-
vention of future attacks. Consequently, there has 
been growing interest in identifying biochemical 
markers that may provide clues to the underlying 
diagnosis of a recent but resolved spell, or perhaps 
might even contribute directly to the underlying 
problem. In this regard, certain neuropeptides 
(NPs) or peptide hormones (PHs) that are released 
into the circulation under conditions of stress have 
attracted particular interest (Tables 1, 2).
It is recognized that studies of the potential 
value of NPs and PHs in pinpointing likely causes of 
syncope and/or OI in given patients, and in providing 
greater insight into the pathophysiology of these 
conditions has only just begun. Nonetheless, the 
goal of this review is to summarize current under-
standing and identify topics that may merit future 
investigation. For convenience, the abbreviation NP 
will be used to indicate both NPs and PHs.
Syncope and OI
As noted above, while syncope and OI have 
many potential causes (Fig. 1), those conditions 
that result in a ‘functional’ disturbance of ANS­CVS 
control are by far the most common [1]. In most 
instances the functional abnormality is transient 
and unpredictable in nature, and triggers syncope 
or near­syncope (or perhaps ‘lightheadedness’) qui-
te unexpectedly; vasovagal syncope and situational 
reflex faints are the best examples. However, chro-
nic functional disturbances of ANS-CVS control 
may also occur, leading to long-standing disability. 
The most widely recognized example of this is 
the multi-faceted postural orthostatic tachycardia 
syndrome (POTS), but other less well recognized 
conditions almost certainly exist [4, 5]. On the 
other hand, not all forms of ‘functional’ reflex 
syncope conditions fit neatly into the ‘transient’ 
or ‘chronic’ categories. For instance, carotid sinus 
syndrome (CSS) is intermittent and is similarly 
unpredictable in terms of the triggering of a symp-
tomatic neural reflex; however, CSS is usually asso-
ciated with chronic underlying predisposing factors 
such as carotid vascular atheromatous disease or 
neck muscle (particularly sternocleidomastoid) 
neural deafferentation. The latter may adversely 
Figure 1. Classification and principal causes of syncope and orthostatic intolerance; ANS — autonomic nervous 
system, CNS — central nervous system; CSS — carotid sinus syndrome; CVS — cardiovascular system; HD — heart 
disease; HOCM — hypertrophic cardiomyopathy; MSA — multiple system atrophy; PAF — pure autonomic failure; 
POTS — postural orthostatic tachycardia syndrome; VVS — vasovagal syncope.
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affect proprioception of neck position, and thereby 
inappropriately trigger a baroreceptor reflex.
Compromise of cerebrovascular and other 
organ perfusion in a given individual may also 
occur as a consequence of coexisting disease 
processes (e.g., structural heart disease and car-
diac arrhythmias, diabetes, renal failure), or the 
adverse effects of prescribed medications. These 
latter circumstances are very common, and in older 
individuals are a major source of syncope and OI. 
Finally, and least frequent but having a worrisome 
prognosis are progressive diseases of the nervous 
system (Table 3). These conditions are fortunately 
relatively uncommon causes of syncope or OI in 
the general population, and are best cared for by 
neurologists.
ANS disturbances in syncope and OI
The ANS is comprised of a complex network 
of neural fibers, central connections, chemical 
transmitters, and enzymes that ultimately control 
the function of all organ systems [3]. In health, 
the ANS is responsible for appropriate modula-
tion of critical physiological functions including 
regulation of respiratory, blood pressure and 
cardiac inotropic and chronotropic states, body 
temperature, and gastrointestinal, endocrine and 
genitourinary status. For the most part, ANS acti-
vity operates unnoticed, with its principal arms 
(i.e., sympathetic and parasympathetic nervous 
systems) balancing organ function as required 
with changing metabolic needs. Unfortunately, 
a number of conditions may undermine normal ANS 
function (Table 3), and in terms of affecting the 
CVS, the result may be intermittent hypotension 
and syncope or other manifestations of presumed 
ANS-CVS instability that require an excessive and 
symptom-inducing compensatory response, such 
as the sinus tachycardia in POTS. Further, given 
the ANS’s universal role in organ system function, 
a multitude of concomitant symptoms associated 
with a variety of organs should not be a surprise. 
Thus syncope associated with chronic or tem-
porary ANS dysfunction is often accompanied at 
some stage by abnormal temperature regulation, 
disturbances of hearing, disturbed respiratory and 
cardiac rate, gastrointestinal upset, a lightheaded 
sensation and fatigue.
Table 1. Main sites of origin of neuropeptides/peptide hormones assessed to date for syncope and  
orthostatic intolerance.
Neuropeptide Brain and/or 
nerves
Heart Vessels Gastrointestinal  
tract
 Kidneys
B-type natriuretic peptide      
Atrial natriuretic peptide       
Adrenomedullin      
Endothelin (1-3)       
Galanin     
Vasoactive intestinal peptide      
Vasopressin       
Table 2. Primary actions of neuropeptides/peptide hormones.
Neuropeptide Vasodilation Vasoconstriction Inhibition of the  
renin–angiotensin system
Diuresis
B-type natriuretic peptide  
Atrial natriuretic peptide  
Adrenomedullin 
Endothelin (1-3)  
Galanin   
Vasoactive intestinal peptide  
Vasopressin 
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While temporary functional disturbances of 
ANS-CVS interaction account for most forms of 
syncope, other less common ANS morbidities 
should not be overlooked (Table 3). These include 
Parkinson’s disease, pure autonomic failure and 
multiple system atrophy. Additionally, uncommon 
inflammatory conditions, such as Guillan­Barré, 
may merit consideration. In all of these cases, 
the essential pathophysiology is transient failure 
of blood pressure control resulting in self-limited 
cerebral hypo-perfusion that cannot be fully comp-
ensated for by cerebrovascular auto-regulation [4].
As a group, conditions causing disturbances 
of ANS function may markedly limit an affected 
individual’s ability to carry out activities of daily 
living and thereby undermine quality-of-life, and 
may result in substantial economic loss due to 
loss of employment and cost of care. In many in-
stances, particularly in older patients susceptible 
to orthostatic hypotension (OH), ANS dysfunction 
is also associated with increased morbidity and 
mortality, due primarily to greater potential for 
falls and injury.
Neuropeptides as potential diagnostic  
tools in syncope evaluation
A number of groups have studied the useful-
ness of common cardiac biomarkers in the diag-
nostic and prognostic assessment in patients with 
syncope. The rationale for use of NPs is primarily 
that they may be elevated in syncope patients for 
an extended period of time after symptoms have 
resolved; this would be expected particularly in 
individuals with cardiovascular disease and impai-
red hemodynamics, and might thereby suggest an 
arrhythmic or structural cardiac disorder as the 
basis for symptoms.
Only a few studies have to date assessed the 
potential value of NPs to help identify the CVS 
origin for syncope or near syncope. For instance, 
Tanimoto et al. [6] examined retrospectively the 
usefulness of B-type natriuretic peptide (BNP) 
as a marker for distinguishing cardiac from non-
-cardiac causes of syncope. They evaluated BNP 
concentrations in 148 consecutive syncope pa-
tients. The ‘gold standard’ for cardiac syncope 
was deemed to be evidence for one of the follo-
wing conditions: aortic stenosis, hypertrophic 
cardiomyopathy, pulmonary embolism, cardiac 
tamponade, ventricular tachycardia, or bradycar-
dia. A BNP cut-off value of 40 pg/mL and above 
was used to assign a cardiac cause of syncope; 
they reported that the sensitivity and specificity 
values for identification of cardiac syncope were 
82% and 92%, respectively (Fig. 2).
Unfortunately, the study by Tanimoto et al. 
[6] has a number of important limitations. Most 
importantly, as is evident from Figure 2 modified 
from their publication, the overlap between cardiac 
and non-cardiac causes is too great to provide 
a useful clinical test. Perhaps a BNP ≥ 75 pg/mL 
would have more effectively excluded non-cardiac 
causes of syncope in their patients. Secondly, 
being retrospective, the reliability of the original 
clinical diagnosis is not verifiable. Finally, given 
the potential seriousness of cardiac syncope, 
a useful clinical diagnostic screening test must offer 
much higher sensitivity so as to avoid missing 
possible cases.
More recently, Pfister et al. [7] proposed 
N-terminal B-type natriuretic peptide (NT-proBNP) 
as a prognostic predictor of adverse outcome 
among syncope patients being evaluated in the 
Emergency Department (ED). NT-proBNP levels 
were significantly higher in patients with cardiac 
compared to non-cardiac syncope. At a cut-off value 
of 156 pg/mL, NT-proBNP showed a sensitivity of 
Table 3. Principal autonomic disorders (after 
Mathias et al. [3]).
PRIMARY
Chronic autonomic failure syndrome
Pure (primary) autonomic failure
Multiple system atrophy
Autonomic failure with Parkinson’s disease
SECONDARY
Metabolic diseases
Diabetes mellitus
Chronic renal failure
Chronic liver disease
Alcoholic toxicity
Inflammatory disease
Guillain-Barre syndrome
Transverse myelitis
Autosomal recessive trait
Familial dysautonomia (Riley-Day)
Dopamine beta-hydroxylase deficiency
Autosomal dominant
Familial amyloid neuropathy
Trauma
Spinal cord trauma
Autonomic reflex faints and  
postural tachycardia syndrome
See text
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89.7%, a specificity of 51.8% and a negative pre-
dictive value of 84.3% for the diagnosis of cardiac 
syncope. Increasing NT­proBNP was a significant 
predictor of cardiac syncope (OR 3.7, 95% CI 
2.3–5.8 per standard deviation of Log NT-proBNP, 
p < 0.001) and addition of NT­proBNP significantly 
improved a predictive model including heart rate, 
history of structural heart disease and abnormal 
electrocardiogram. An important criticism of this 
evaluation is that the study was performed on ho-
spitalized patients with the results being directly 
translated to a risk stratification approach of the 
newly arriving patient in the ED.
In summary, the role of NPs, particularly BNP 
and NT-proBNP diagnostic screening in the ED or 
urgent care environment is appealing but the find­
ings to date are unconvincing. Currently, patients 
in whom an explanation for syncope is not found 
during the initial evaluation and who are judged as 
being at increased risk are hospitalized and undergo 
a time and resource-consuming diagnostic procedu-
re. There is clearly a need for improved diagnostic 
capabilities and clinical parameters in a triage 
setting. Biomarkers such as BNP and NT-proBNP, 
which are available widely as a commercial assay, 
could provide a low cost tool for risk stratification. 
Further evaluation is needed.
Neuropeptides and peptide hormones in 
the pathophysiology of reflex syncope
Reflex syncope refers to a heterogeneous 
group of conditions in which cardiovascular reflex­
es, that normally act to stabilize the circulation 
and allow it to respond to conditions of stress or 
exertion, become transiently inappropriate. The 
triggers are sometimes clear-cut (e.g., pain, emo-
tional upset, micturition), but often that is not the 
case. The adverse outcome is typically veno- and 
vaso-dilatation and marked or relative bradycardia. 
If sufficiently severe, arterial blood pressure may 
fall, and global cerebral hypo-perfusion may cause 
syncope. Additionally, as noted earlier, multiple 
organ systems other than the CVS are affected, 
and gastrointestinal, respiratory and constitutional 
(e.g., fatigue) symptoms commonly accompany the 
hypotension.
Vasovagal syncope (VVS) is the most common 
of the group of reflex (neurally­mediated) syncope 
conditions, and several studies have assessed neuro- 
 humoral changes accompanying VVS by use of 
head-up tilt-table testing. In this regard, changes 
in circulatory catecholamines have tended to be 
of greatest interest given the apparent association 
of VVS with anxiety or stress states [8–14]. How-
ever, the potential role of NPs has also attracted 
attention; specifically, BNP [8], vasopressin (VP) 
[8, 15, 16], atrial natriuretic peptide (ANP) [8, 17], 
adrenomedullin (ADM) [17–19], galanin (GAL) 
[19, 20], and endothelin-1 (ET-1) [17, 21–23]. 
A summary of the primary physiologic effects of 
these NPs is shown in Table 2.
Vasopressin
Vasopressin was among the first NPs (or 
‘peptide hormones’) to be evaluated as a potential 
contributor to VVS pathophysiology [8, 15, 16]. All 
studies agree that at the time of tilt-table induced 
reflex syncope VP levels are elevated. By way of 
example, Jardine et al. [8] observed a statistically 
significant VP increase 5 min before symptoms, 
with an even greater excess occurring at the time 
of syncope. However, in other reports an increase 
in VP levels occurred during upright tilt in both 
subjects who eventually develop syncope and those 
who do not faint [15]. VP has also been reported 
to exhibit a biphasic increase: first at 3 to 7 min of 
upright tilt in both normal controls and those who 
faint, and again at 45 min in controls and at the time 
of syncope in those who faint [15].
Figure 2. Findings comparing B-type natriuretic peptide 
(BNP) values in patients deemed to have cardiac and 
non-cardiac causes of syncope. Note the substantial 
overlap of values. See text for discussion. The graph 
has been modified after Tanimoto et al. [6].
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In any event, the manner in which VP might 
enhance VVS susceptibility is unclear. Jardine et 
al. [8] hypothesized that VPs direct pressor effect 
may be overcome by an indirect effect enhancing 
arterial and ventricular mechanoreceptor activity; 
however, other reports suggest that carotid baro-
receptor activity is down-regulated by VP. Clearly, 
further study of VP-baroreceptor interaction is 
needed.
ANP and BNP
Jardine et al. [8] examined BNP and ANP levels 
during head-up tilt testing in control subjects and 
individuals who developed reflex syncope. BNP did 
not differ appreciably in the two patient groups and 
consequently is not likely to play a pathophysiologi-
cal role. ANP levels tended to be higher throughout 
the study in syncope-prone patients compared to 
controls. However, in both groups, ANP values fell 
slowly and comparably during the period of extended 
upright posture, but were not appreciably altered by 
whether syncope occurred or not.
Fedorowski et al. [17] recently examined the 
relationships between certain NPs and mecha-
nisms underlying syncope in a series of patients 
with unexplained transient loss of consciousness 
undergoing head-up tilt table testing; a cardiac 
etiology for symptoms was deemed excluded by 
the initial clinical evaluation. They studied the mid-
-regional fragments of pro-atrial natriuretic peptide 
(MR­proANP); findings revealed that ANP levels 
tended to be lowest in patients prone to tilt-indu-
ced fainting and highest in non-fainters (Fig. 3). 
Taken together, the observations of Jardine et al. 
[8] and Fedorowski et al. [17] may be reasonably 
interpreted to reflect the impact of progressively 
diminished atrial stretch during upright posture, 
with NP’s acting to provide a fluid conservation 
state particularly in syncope-prone individuals.
Galanin
Galanin (GAL) is a neuropeptide that is widely 
distributed in the central and peripheral nervous 
systems. GAL interacts with both sympathetic and 
vagal systems as well as with neurotransmitters, 
such as serotonin. In animals, GAL can lower blood 
pressure and attenuate vagally-induced slowing of 
the heart rate. In humans, the administration of 
GAL depresses basal norepinephrine and norepi-
nephrine responses to both assumption of upright 
posture and insulin-induced hypoglycemia.
Bondanelli et al. [19] examined plasma GAL 
changes during head-up tilt test (HUTT) in he-
althy subjects and patients with recurrent VVS. In 
healthy control subjects, GAL did not change during 
HUTT. However, GAL levels increased in VVS 
patients who did not develop syncope (negative 
HUTT), whereas it remained unchanged in VVS 
patients who developed syncope (positive HUTT).
Plasek et al. [20] obtained slightly different 
results from the Bondanelli et al. study [19]. GAL 
increase differentiated cases from controls better 
than it differentiated positive and negative respon-
ses to HUTT, i.e. there was an increase in plasma 
GAL for VVS patients during HUTT, regardless of 
whether they developed syncope or not during the 
test. Overall despite the controversies on the role 
of GAL in VVS, GAL might be useful as a marker 
of VVS recurrence.
Endothelin
Kaufmann et al. [22] and White et al. [23] 
provided early observations on the association 
between plasma endothelin levels and outcomes 
during upright tilt. Kaufmann et al. [22] noted that 
Figure 3. Findings illustrating the inverse relationship 
between atrial natriuretic peptide (ANP) values and ten-
dency to positive head-up tilt test (HUTT) result in pa-
tients with vasovagal syncope. The ordinate indicates 
the number of subjects with a positive (solid line) or 
negative (dashed line) HUTT. The abscissa depicts neu-
ropeptides values by quartile range with highest values 
at the left. The largest number of positive HUTT’s ten-
ded to be associated with low ANP values. Conversely, 
patients with negative HUTT tended to have highest 
ANP levels; MR-proANP — mid-regional fragments of 
pro-ANP. Graph modified after Fedorowski et al. [17].
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plasma endothelin (and VP) rose in VVS patients; 
this did not occur in autonomic failure patients. 
Conversely, White et al. [23] did not observe any 
increase in ET-1 among VVS susceptible subjects, 
but did in non-fainters. More recently, Fedorowski 
et al. [17] re-assessed the relationships between 
C-terminal endothelin-1 precursor fragment (CT-
-proET-1) and the main mechanisms underlying 
syncope diagnosed during head-up tilt in a series 
of patients with unexplained transient loss of 
consciousness. Consistent with the observations 
of White et al. [23], in neurally-mediated syncope, 
ET-1 production was down-regulated.
Neuropeptides in postural  
tachycardia syndrome
Postural tachycardia syndrome is principally 
characterized by excessive sinus tachycardia when 
the affected individual is in the upright position; ho-
wever, it is frequently also accompanied by numerous 
other symptoms (e.g., dizziness, fatigue, exercise 
intolerance, etc.). POTS remains a condition that has 
proved clinically very challenging. Little is known of 
the potential role of vasoactive NPs in this condition, 
except for one study examining adrenomedullin 
(ADM) levels in children with presumed POTS.
Adrenomedullin
Adrenomedullin is a vasodilator (acting through 
nitric oxide) and a natriuretic agent that increases 
glomerular filtration. It is widely accepted that 
measurement of the concentration of a more stable 
mid-regional fragment of pro-ADM (MR-proADM) 
is a suitable surrogate for ADM concentration.
Zhang et al. [18] examined the predictive value 
of the MR-proADM in assessing the therapeutic 
efficacy of midodrine hydrochloride for children 
with POTS. The authors reported higher levels of 
MR-proADM in otherwise healthy children with 
a clinical diagnosis of POTS compared with normal 
controls. Further, they concluded that MR-proADM 
> 61.5 pg/mL provided a useful cut-off to predict 
effectiveness of therapy with midodrine. Finally 
they observed that the higher the ADM level, the 
greater the midodrine effectiveness; the finding is 
at best counter-intuitive.
In an editorial [10] accompanying the article by 
Zhang et al. [18], concerns were raised regarding 
the study design, the midodrine dose employed, 
and the physiological mechanism for the apparent 
efficacy of midodrine in patients with elevated 
ADM. Excluding concerns related to the utility of 
midodrine in POTS patients, the possibility that 
vasoactive peptides, particularly ADM, contribute 
to the pathophysiology of POTS is intriguing. Even 
if NPs are epiphenomena in POTS, the study from 
Zhang et al. [18] raises the prospect of utilizing 
vasoactive peptide concentrations as useful quan-
titative markers of POTS severity, and potentially 
as a means other than symptom status that can be 
tracked in individual patients as treatments are 
introduced.
Neuropeptides in OH/syncope
The term ‘orthostatic hypotension’ describes 
a condition in which the ANS fails to maintain 
a stable blood pressure in the face of orthostatic 
stress. OH is generally defined as a reduction in 
a systolic blood pressure of at least 20 mm Hg or 
diastolic blood pressure of at least 10 mm Hg with 
3 min of standing [1]. However, a smaller fall in 
blood pressure that is associated with symptoms 
can be of equal importance, as can a slow but steady 
decline in blood pressure over a somewhat longer 
period (10–15 min).
A variety of conditions can result in failure of 
orthostatic blood pressure control; these causes 
are often classified into primary and secondary. 
Primary causes of OH are for the most part idio-
pathic, whereas secondary forms are usually asso-
ciated with a particular disease (such as diabetes), 
pharmacotherapy (e.g., diuretics, vasodilators), or 
a known biochemical or structural abnormality. The 
latter conditions include pure autonomic failure 
characterized by widespread evidence of autonomic 
failure as well as OH, but with no other neurologic 
involvement, and multiple system atrophy (once 
known as Shy-Drager syndrome), a sporadic, pro-
gressive and ultimately fatal disorder characterized 
by OI and widespread evidence of ANS dysfunction 
together with manifestations of Parkinsonism and 
cerebellar ataxia, alone or in combination [3]. Some 
patients with classic Parkinson disease may also 
develop signs of ANS failure, including OH.
A number of pharmacologic agents may pro-
duce or exacerbate OH. These agents include 
tricyclic antidepressants, ethanol, angiotensin-
­converting enzyme inhibitors, alpha­receptor 
blockers, calcium channel blockers, phenothiazines, 
opiates, bromocriptine, and beta-blockers. Therapy 
includes increasing dietary fluid and salt intake, 
exercise, and compression garments in addition 
to discontinuing the use of offending agents, if pos-
sible. Volume expanders such as fludrocortisone 
acetate and vasoconstrictors such as midodrine 
hydrochloride may be useful in selected patients.
www.cardiologyjournal.org 597
Balaji Krishnan, David G. Benditt, Neuropeptides 
In most cases, careful clinical evaluation is 
usually able to identify a likely etiology for OH; 
however, in approximately 20–40% of cases the 
cause is unknown. Extrinsic pharmacologic agents 
(e.g., diuretics and vasodilators) are well-known 
causes of OH as noted above; however the possi-
bility exists that intrinsic neurohumoral agents 
with similar properties may be a contributing factor 
was initially suggested by observations in certain 
paraneoplastic syndromes; specifically, findings in 
small cell lung cancer in which elevated ANP was 
associated with OH [24].
Several intrinsic NPs including BNP and 
NT-proBNP, ANP, and ADM exhibit diuretic and 
vasodilator properties. Although these NPs are usu-
ally only elevated in volume overload states, excess 
NP related to tumors or inflammatory conditions 
has been previously observed, and associated with 
OH in some cases.
ANP and BNP
As noted above, Fedorowski et al. [17] asses-
sed several NPs in various forms of syncope. ANP 
levels were not markedly altered in OH. On the 
other hand, with respect to BNP, we recently noted 
correspondence between OH symptoms and NT-
-proBNP levels in euvolemic patients without other 
OH explanation; most had a prior history of solid or-
gan transplants or inflammatory disease. In healthy 
subjects, plasma BNP levels are low (< 300 pg/mL). 
The major stimulus for BNP release is mechanical 
myocyte stress usually due to ventricular volume 
and/or pressure overload as may occur in hypervole-
mic systolic heart failure [25]. However, apart from 
renal excretion other factors such as marked obesity 
and inflammation may modify circulating BNP and 
NT-proBNP concentrations [26]. Obesity lowers 
pro­BNP, and inflammation through its effects on 
cytokines increases NT-proBNP, albeit modestly and 
not to the levels noted in our cohort [27, 28]. Serum 
levels of NT-proBNP have been associated with 
allograft function in recipients of renal transplants 
[29]. Median NT-proBNP in renal transplant patients 
reach levels of 500–600 pg/mL in patients with 
estimated glomerular filtration rate > 60 mL/min. 
Levels are typically elevated in patients with de-
layed graft function and hypervolemia. In the same 
study, the type of immunosuppression did not play 
a role in NT-proBNP levels. Our group of renal trans-
plant patients did not have delayed graft function 
dysfunction, and were euvolemic or hypovolemic 
on presentation.
In heart failure, the known natriuretic, diure-
tic and vasorelaxant properties of BNP induce an 
increase in effective renal plasma flow, glomerular 
filtration rate, urine flow rate, and sodium excre-
tion. ANP has similarly been shown to inhibit po-
stural release of renin and VP in healthy humans. 
The increase in NP levels has been considered 
to represent an intrinsic compensatory response 
to volume excess. Prolonged BNP release in the 
absence of volume overload, as has been reported 
with certain malignancies might be expected to 
trigger OH. Potential extracardiac sources of BNP 
secretion include the central nervous system, 
lung, thyroid, adrenal glands, kidney, spleen, small 
intestine, ovary, uterus and striated muscle. To 
date, however, there are no reports of non-cardiac 
sources resulting in sustained high NT-proBNP le-
vels comparable to those observed in our patients.
Vasopressin
Vasopressin appears to play a role in mode-
rating any tendency to hypotension induced by 
upright posture. Head-up posture should be asso-
ciated with increased VP levels, thereby providing 
a positive pressor response [30]. Further, the 
appropriateness of VP response to upright posture 
may serve as a means of assessing the integrity of 
central baroreflex arcs.
Endothelin-1
In OH, Fedorowski et al. [17] observed hype-
ractivity of the endothelin system. They reported 
a strong linear relationship between increasing supine 
CT-proET-1 levels and orthostatic instability (Fig. 4). 
Since ET-1 is one of the most potent vasocon-
strictors, producing a sustained increase in blood 
pressure, up-regulation of ET-1 production may be 
a way to compensate for a hypotensive tendency 
during orthostasis. Suppression of the endothelin 
system was highly suggestive of a cardioinhibitory 
reflex. Therefore, endothelin level may suggest 
a diagnosis of either ‘pure’ vasovagal reflex (low 
concentration) or OH (high concentration), the latter 
indicating a tendency towards dominant vasodilation.
Conclusions
A wide range of NPs and PHs have been iden-
tified, and many exert cardio­active effects that 
could in theory prove helpful in identifying causes 
of syncope, or even explaining the pathophysiology 
of certain syncope syndromes. To date, the princi-
pal NP/PHs that have been studied in this context 
are: ANP, ADM, BNP, ET-1, GAL, and VP. Findings 
are as yet not definitive. However, the intrinsic 
vasoconstrictor ET-1 may be elevated in some OH 
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Figure 4. Findings illustrating the direct relationship 
between endothelin-1 (ET-1) values and tendency to 
positive head-up tilt test (HUTT) result in patients with 
orthostatic syncope. The ordinate indicates the num-
ber of subjects with a positive (solid line) or negative 
(dashed line) HUTT. The highest ET-1 levels are at the 
right on the abscissa. A positive orthostatic response 
on HUTT tended to be associated with the highest ET-1 
values suggesting a possible compensatory respon-
se; CT-proET-1 — C-terminal ET-1 precursor fragment. 
Graph modified after Fedorowski et al. [17].
cases presumably in an attempt to compensate for 
vasodilation and hypotension of other etiologies. As 
such ET-1 may be a useful marker for OH. Conver-
sely, elevated NT-proBNP may play a role in causing 
vasodilation and hypotension in some forms of OH 
of unknown cause, and may be a marker in other 
patients of a cardiovascular cause of syncope. The 
contributions of other NPs are even more uncertain. 
In the end, the study of NP/PHs in syncope and OI 
syndromes has just begun, and considerable further 
future effort will be needed to clarify their possible 
contributions to these conditions.
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